Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd-line therapy for relapsed and refractory multiple myeloma - a phase II trial

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

(2016) T. Plesner et al.   BLOOD

Multiple myeloma: patient outcomes in real-world practice

(2016) Kwee Yong et al.   BRITISH JOURNAL OF HAEMATOLOGY

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

(2016) Sagar Lonial et al.   LANCET

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

(2016) Philippe Moreau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

(2016) Meletios A. Dimopoulos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma

(2015) Shaji K Kumar et al.   AMERICAN JOURNAL OF HEMATOLOGY

Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma

(2015) J. J. Shah et al.   BLOOD

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

(2015) Sagar Lonial et al.   NEW ENGLAND JOURNAL OF MEDICINE

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

(2015) A. Keith Stewart et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

(2015) Henk M. Lokhorst et al.   NEW ENGLAND JOURNAL OF MEDICINE

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

(2014) P. G. Richardson et al.   BLOOD

Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial

(2014) P. Rodon et al.   HAEMATOLOGICA

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma

(2013) H. Ludwig et al.   BLOOD

Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077

(2013) Wolfram Pönisch et al.   BRITISH JOURNAL OF HAEMATOLOGY

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

(2013) Jesus San Miguel et al.   LANCET ONCOLOGY

Association of response endpoints with survival outcomes in multiple myeloma

(2013) S Lonial et al.   LEUKEMIA

Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study

(2013) M Offidani et al.   Blood Cancer Journal

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study

(2012) S. Lentzsch et al.   BLOOD

Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

(2012) James R. Berenson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Toward deeper response in MM

(2011) J. Blade et al.   BLOOD

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

(2011) F. Gay et al.   BLOOD

Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and ‘retreatment’ approaches in the era of novel agents

(2011) B Mohty et al.   LEUKEMIA

The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies

(2011) M S van der Veer et al.   Blood Cancer Journal

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

(2010) J.-L. Harousseau et al.   BLOOD

Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial

(2010) P. Moreau et al.   BLOOD

Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma

(2010) J.-L. Harousseau et al.   HAEMATOLOGICA

Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents

(2010) Asher A. Chanan-Khan et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of complete response in multiple myeloma

(2009) J.-L. Harousseau et al.   BLOOD

Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)

(2009) S. Knop et al.   BLOOD

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma

(2009) Edward A. Stadtmauer et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

(2009) M A Dimopoulos et al.   LEUKEMIA

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma

(2008) Ruben Niesvizky et al.   BRITISH JOURNAL OF HAEMATOLOGY

Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial

(2008) Wolfram Pönisch et al.   BRITISH JOURNAL OF HAEMATOLOGY

Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival

(2008) Juan José Lahuerta et al.   JOURNAL OF CLINICAL ONCOLOGY

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

(2008) R A Kyle et al.   LEUKEMIA